Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors

NCT05746897 is registered in ClinicalTrials.gov with Hefei TG ImmunoPharma Co., Ltd. as lead sponsor.

NCT NCT05746897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05746897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors
Lead sponsor
Hefei TG ImmunoPharma Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
April 13, 2023
Completion date
September 30, 2027
Enrollment
38 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, melanoma, ovarian cancer, triple negative breast cancer